Adaptive Biotechnologies (NASDAQ: ADPT)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Adaptive Biotechnologies Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adaptive Biotechnologies Company Info
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
News & Analysis
The company could see its first FDA-approved therapy as early as next year.
The American Society of Clinical Oncology (ASCO) just finished up its annual meeting. We have some winners coming out of the conference.
Because of this stock market crash, some wonderful stocks are super cheap in 2022. Here's a mini-portfolio of innovative companies trading under $10 a share right now.
The CEO of Ark Invest hasn't given up on these risky biotech stocks.
ARK Invest made multiple purchases of these stocks last week.
Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.
Does this unusual biotech stock have what it takes to deliver market-beating gains?
Investors expect the company's technology platform to come in handy as the world corrals the coronavirus pandemic.
Valuation
Earnings Transcripts
ADPT earnings call for the period ending June 30, 2022.
ADPT earnings call for the period ending March 31, 2022.
ADPT earnings call for the period ending December 31, 2021.
ADPT earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.